A patient with severe obesity experienced a temporary loss of appetite during treatment with Mounjaro. Deep brain recordings showed that Mounjaro and Zepbound temporarily suppressed the activity of brain circuits associated with food cravings. Specifically, they silenced the nucleus accumbens, which is the brain's reward center, thereby reducing obsessive thoughts about food. After the drug stopped working, the appetite returned. This effect confirms that drugs such as Mounjaro and Zepbound can affect brain mechanisms regulating appetite and food cravings in obese patients. Mounjaro is approved for the treatment of type 2 diabetes, while Zepbound is approved for long-term weight control in obese or overweight people with associated health problems. Clinical studies have shown that these drugs can lead to significant weight loss, with patients taking the highest doses achieving an average weight loss of around 20% or more[1][2][4].